Lifeboat Foundation

There are approximately 425 million people worldwide with diabetes. Approximately 75 million of these inject themselves with insulin daily. Now, they may soon have a new alternative to syringes or insulin pumps. Scientists have found a new way to supply the body with smart insulin.

The new insulin can be eaten by taking a capsule or, even better, within a piece of chocolate.

Inside these are tiny nano-carriers in which the insulin is encapsulated. The particles are 1/10,000th the width of a human hair and so small that you cannot even see them under a normal microscope.

In the presence of protospacer adjacent motif (PAM), sgRNA accurately leads the Cas9 endonuclease to the target regions, where it causes DNA double strand breaks (DSBs), resulting in site‐specific genomic change. Endogenous DNA repair can take place following the creation of a DSB via two primary genome editing pathways: nonhomologous end joining (NHEJ) or homology‐directed repair (HDR).

By using the biological characteristics of Cas9 targeting specific DNA sequences under the guidance of sgRNA, scientists have further developed gene targeting activation and gene targeting inhibition tools based on dCas9, called CRISPRa and CRISPRi respectively.

In the paper, characteristics of three forms of CRISPR/Cas9 cargos are outlined. Three delivery forms of the CRISPR/Cas9 system are plasmids, mRNA/sgRNA, and ribonucleoprotein (RNP) complexes, each of which has its own advantages and disadvantages.

A new test measures genomic changes in thyroid biopsy samples and generates a score based on how strongly each change is associated with thyroid cancer.

Colorectal cancer (also called bowel cancer) typically develops in the large bowel (colon) or rectum. Recent studies have shown significant rises in the number of colorectal cancer cases, particularly those in young adults. As we discussed earlier, the recently released estimated cancer statistics for 2024 predict colorectal cancer as the leading cause of mortality in men under 50 and the second-leading cause of mortality in women. Additionally, experts predict over 150,000 new cases of colorectal cancers this year.

To combat these troubling figures, ongoing research focused on the prevention and treatment of colorectal cancers remains a high priority and urgent need. This includes data recently published in Science Advances which demonstrates pre-clinical efficacy for a new treatment approach.

The study involves genetic material known as microbial or mislocalized DNA. This type of DNA arrises from cells that become damaged, thus no longer providing the correct genetic instructions. Damaged DNA can elicit various reactions in the body, including activating the immune response. Damaged DNA can therefore influence how the body responds to diseases, including colorectal cancer.

Researchers have overcome a major challenge in biomimetic robotics by developing a sensor that, assisted by AI, can slide over braille text, accurately reading it at twice human speed. The tech could be incorporated into robot hands and prosthetics, providing fingertip sensitivity comparable to humans.

Human fingertips are incredibly sensitive. They can communicate details of an object as small as about half the width of a human hair, discern subtle differences in surface textures, and apply the right amount of force to grip an egg or a 20-lb (9 kg) bag of dog food without slipping.

Continue reading “Breakthrough could see robots with ‘fingertips’ as sensitive as humans” »

Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University have investigated in mice how spreading tumor cells behave at the site of metastasis. Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status. This was also confirmed in experiments with human tumor cells. The results of the study could pave the way for novel diagnostic and therapeutic applications.

The work appears in Nature Cancer.

What makes cancer so dangerous? Cancer cells that leave the primary tumor to reach distant sites of the body where they may grow into daughter tumors, called metastases. While most primary tumors can be effectively treated, metastases are the real danger. Oncologists estimate that more than 90% of all cancer deaths in solid tumors are due to metastases.

Nanotechnology offers specific benefits that will enable the future of cancer care. Find out here what these are.

A gene editing tool using a system known as CRISPR-Cas9 has recently been approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease. The drug is known as Casgevy and the media has hailed this treatment as a ‘cure’ for sickle cell anemia patients. While it is still unclear if the drug completely cures these patients, clinical trials show exciting efficacy.

Sickle cell disease is a genetic blood disorder affecting thousands of US citizens. Many of these patients are African American and Hispanic. In sickle cell disease, hemoglobin, a protein in red blood cells that helps carry oxygen throughout the body, is mutated. As a result, blood cells change shape in the form of a sickle, giving the disease its name. Unfortunately, the mutated cells cause disruption of blood flow and prevent other blood cells from delivering oxygen to the body. This disease is extremely rare and can lower the quality of life in patients. Previously, there were limited treatments options including transfusions and medications for pain management. However, Casgevy provides a new option to help treat the patient and relieve pain for over a year after a single treatment.

One-time treatment using Casgevy improved life quality for sickle cell patients. A single-arm trial was conducted at multiple health centers in adults and adolescents. These patients were screened for two vaso-occlusive crises (VOCs) which are described as severely painful events due to a lack of oxygen delivery from sickle cell blood cells blocking blood flow. The primary measure of success in the trial was the number of VOCs after treatment. In total, 44 patients received Casgevy and 33 were able to follow up and be evaluated. Of the 33 patients that made it through the trial, 29 of them did not experience any VOCs for 12 months. This is a 93.5% success rate based on the number of patients that were analyzed. All 44 patients were able to successfully undergo treatment without any graft rejection. In addition, researchers concluded that this treatment was not only effective, but safe with few side effects.

Our very old immune systems can’t keep up with modern lifestyles and diets, leading to increases in all sorts of chronic health problems like allergies and obesity.